Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells
Name:
36411320.pdf
Size:
25.22Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Halbrook, C. J.Thurston, G.
Boyer, S.
Anaraki, C.
Jiménez, J. A.
McCarthy, Amy
Steele, N. G.
Kerk, S. A.
Hong, H. S.
Lin, L.
Law, F. V.
Felton, C.
Scipioni, L.
Sajjakulnukit, P.
Andren, A.
Beutel, A. K.
Singh, R.
Nelson, B. S.
Van Den Bergh, F.
Krall, A. S.
Mullen, P. J.
Zhang, L.
Batra, S.
Morton, J. P.
Stanger, B. Z.
Christofk, H. R.
Digman, M. A.
Beard, D. A.
Viale, A.
Zhang, J.
Crawford, H. C.
Pasca di Magliano, M.
Jorgensen, Claus
Lyssiotis, C. A.
Affiliation
Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USAIssue Date
2022
Metadata
Show full item recordAbstract
The pancreatic tumor microenvironment drives deregulated nutrient availability. Accordingly, pancreatic cancer cells require metabolic adaptations to survive and proliferate. Pancreatic cancer subtypes have been characterized by transcriptional and functional differences, with subtypes reported to exist within the same tumor. However, it remains unclear if this diversity extends to metabolic programming. Here, using metabolomic profiling and functional interrogation of metabolic dependencies, we identify two distinct metabolic subclasses among neoplastic populations within individual human and mouse tumors. Furthermore, these populations are poised for metabolic cross-talk, and in examining this, we find an unexpected role for asparagine supporting proliferation during limited respiration. Constitutive GCN2 activation permits ATF4 signaling in one subtype, driving excess asparagine production. Asparagine release provides resistance during impaired respiration, enabling symbiosis. Functionally, availability of exogenous asparagine during limited respiration indirectly supports maintenance of aspartate pools, a rate-limiting biosynthetic precursor. Conversely, depletion of extracellular asparagine with PEG-asparaginase sensitizes tumors to mitochondrial targeting with phenformin.Citation
Halbrook CJ, Thurston G, Boyer S, Anaraki C, Jiménez JA, McCarthy A, et al. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Nat Cancer. 2022 Nov;3(11):1386-403. PubMed PMID: 36411320. Pubmed Central PMCID: PMC9701142 Therapeutics and T-Knife Therapeutics and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting the GOT1 pathway as a therapeutic approach (US patent numbers 2015126580-A1 and 05/07/2015; US patent numbers 20190136238 and 05/09/2019; international patent numbers WO2013177426-A2 and 04/23/2015). The remaining authors declare no competing interests. Epub 2022/11/22. eng.Journal
Nature CancerDOI
10.1038/s43018-022-00463-1PubMed ID
36411320Additional Links
https://dx.doi.org/10.1038/s43018-022-00463-1Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s43018-022-00463-1
Scopus Count
Collections
Related articles
- Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth.
- Authors: Krall AS, Mullen PJ, Surjono F, Momcilovic M, Schmid EW, Halbrook CJ, Thambundit A, Mittelman SD, Lyssiotis CA, Shackelford DB, Knott SRV, Christofk HR
- Issue date: 2021 May 4
- Pancreatic tumor sensitivity to plasma L-asparagine starvation.
- Authors: Dufour E, Gay F, Aguera K, Scoazec JY, Horand F, Lorenzi PL, Godfrin Y
- Issue date: 2012 Aug
- Promoter demethylation of the asparagine synthetase gene is required for ATF4-dependent adaptation to asparagine depletion.
- Authors: Jiang J, Srivastava S, Seim G, Pavlova NN, King B, Zou L, Zhang C, Zhong M, Feng H, Kapur R, Wek RC, Fan J, Zhang J
- Issue date: 2019 Dec 6
- ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase.
- Authors: Williams RT, Guarecuco R, Gates LA, Barrows D, Passarelli MC, Carey B, Baudrier L, Jeewajee S, La K, Prizer B, Malik S, Garcia-Bermudez J, Zhu XG, Cantor J, Molina H, Carroll T, Roeder RG, Abdel-Wahab O, Allis CD, Birsoy K
- Issue date: 2020 Apr 7
- Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.
- Authors: Dai B, Augustine JJ, Kang Y, Roife D, Li X, Deng J, Tan L, Rusling LA, Weinstein JN, Lorenzi PL, Kim MP, Fleming JB
- Issue date: 2021 Jul 10